UK Biotech Co. Abcam Expands With $170M Epitomics Buy

Law360, New York (March 5, 2012, 1:15 PM EST) -- U.K. life sciences company Abcam PLC has agreed to spend $170 million to acquire U.S. company Epitomics International Inc., which provides antibodies to researchers, as part of a strategy to expand in China and around the world, Abcam announced Monday.

Abcam has entered into its largest-ever acquisition to take advantage of Epitomics' presence in China and to enhance its technology offerings as part of its ambition to become a leading biotechnology company, according to Abcam.

“These are exciting times for Abcam as we continue to source...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.